Skip to main content

Table 1 Characteristics of the children enrolled in the trial for mefloquine and artesunate/dihydroartemisinin model development, mefloquine model validation and pharmacokinetic-pharmacodynamic analysis

From: Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children

Baseline characteristic

Model-building dataset (n = 48)

MQ validation dataset (n = 378)

MQ pharmacokinetic–pharmacodynamic analysis dataset (n = 451)

Value

% or range

Value

% or range

Value

% or range

Demographic characteristics

 Sex (male/female) (no.)

19/29

40/60

183/195

48/52

219/232

49/51

 Median age (year)

2.6

0.6–5.0

2.3

0.5–5.0

2.4

0.5–5.0

 Median body weight (kg)

12

7–17

11

5–18

11

5–19

 Median height/length (cm)

89

66–114

85

62–114

86

60–114

Physiological characteristics

 Total bilirubin (μmol/L)

10

1–77

10

0.4–74

17

0.5–163

 Serum creatinine (μmol/L)

42

3–119

36

2–86

40

3–120

 Haematocrit (%)

31

17–49

30

16–59

30

17–62

 Haemoglobin (g/dL)

10

5–15

9

5–18

9

5–19

 AST (IU)

39

5–302

34

7–576

39

5–680

 ALT (IU)

19

7–449

16

4–378

18

3–814

Baseline parasite counts (no/μL)

 Median at day 0

58,131

3322–190,896

 Median at day 1

280

0–13,816

 Median at day 2

0

0–100

Co-administered drugs

 CYP3A4 inducers (at least for one drug measurement/never) (no.)

7/41

15/85

  1. AST, aspartate aminotransferase; ALT, alanine aminotransferase